Biosimilars

Nominations are now open for The Medicine Maker 2020 Power List.

The potential market for complex generics is substantial, but navigating the FDA’s guidance for proving “sameness” is a real minefield...

The biosimilars market is suddenly booming, but such steep competition means that only the wise will survive.

Global healthcare costs and demands are changing, and it’s time to look beyond mammalian cell lines.

After many years of clinical trial failures in Alzheimer’s disease, pharma sees some positive results – although caution is recommended.

A new not-for-profit company will manufacture important generics in the US

Sitting Down With... Ajaz Hussain, President, National Institute for Pharmaceutical Technology and Education, Minnesota, USA.

Biosimilars had their big break in the US in 2015, but three years later biosimilars are still struggling to make a mark.

Sitting Down With Cyrus Krakaria, President of Biotechnology for Lupin Limited, Biotech Division, India.

WHO is investigating the potential of certain biosimilars in a prequalification pilot program.